JP2015528441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015528441A5 JP2015528441A5 JP2015526733A JP2015526733A JP2015528441A5 JP 2015528441 A5 JP2015528441 A5 JP 2015528441A5 JP 2015526733 A JP2015526733 A JP 2015526733A JP 2015526733 A JP2015526733 A JP 2015526733A JP 2015528441 A5 JP2015528441 A5 JP 2015528441A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- subject
- use according
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 69
- 239000002502 liposome Substances 0.000 claims description 63
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 40
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 35
- 235000012000 cholesterol Nutrition 0.000 claims description 20
- 229910052724 xenon Inorganic materials 0.000 claims description 19
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 18
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 18
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 230000000638 stimulation Effects 0.000 claims description 15
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 14
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 12
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 12
- 239000002577 cryoprotective agent Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 12
- 238000002604 ultrasonography Methods 0.000 claims description 11
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 206010043647 Thrombotic Stroke Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- 230000001732 thrombotic effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 description 79
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 22
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 description 5
- 229940012999 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) Drugs 0.000 description 5
- -1 PEG2000-DPPE Chemical compound 0.000 description 4
- 239000007789 gas Substances 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 2
- 238000010943 off-gassing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682130P | 2012-08-10 | 2012-08-10 | |
| US61/682,130 | 2012-08-10 | ||
| CN201210356929.9A CN103565745A (zh) | 2012-08-10 | 2012-09-21 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| CN201210356929.9 | 2012-09-21 | ||
| PCT/US2013/054349 WO2014026117A2 (en) | 2012-08-10 | 2013-08-09 | Neuroprotective liposome compositions and methods for treatment of stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528441A JP2015528441A (ja) | 2015-09-28 |
| JP2015528441A5 true JP2015528441A5 (https=) | 2016-09-29 |
| JP6297040B2 JP6297040B2 (ja) | 2018-03-20 |
Family
ID=50039028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526733A Active JP6297040B2 (ja) | 2012-08-10 | 2013-08-09 | 脳卒中の治療のための神経保護リポソーム組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10369103B2 (https=) |
| EP (2) | EP2882422B1 (https=) |
| JP (1) | JP6297040B2 (https=) |
| CN (2) | CN103565745A (https=) |
| AU (1) | AU2013299453B2 (https=) |
| CA (2) | CA3132444C (https=) |
| WO (1) | WO2014026117A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| CA3132914C (en) | 2013-03-15 | 2023-11-07 | The Board Of Regents Of The University Of Texas System | Liquids rich in noble gas and methods of their preparation and use |
| US10500227B2 (en) * | 2014-12-03 | 2019-12-10 | University Of Cincinnati | Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease |
| US10456483B2 (en) | 2014-12-03 | 2019-10-29 | University Of Cincinnati | Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease |
| US10792305B2 (en) * | 2015-06-23 | 2020-10-06 | Nobilis Therapeutics, Inc. | Therapeutic immune modulation using noble gas compositions |
| EP3158992A1 (en) * | 2015-10-21 | 2017-04-26 | Universität Heidelberg | Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules |
| CZ307851B6 (cs) * | 2017-02-14 | 2019-06-26 | Ústav experimentální medicíny AV ČR, v. v. i. | Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění |
| JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
| EP3628309A1 (en) | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| JP7716076B2 (ja) * | 2021-02-04 | 2025-07-31 | 学校法人産業医科大学 | 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法 |
| JP2022144013A (ja) * | 2021-03-18 | 2022-10-03 | 橋本電子工業株式会社 | 抗血栓リポソーム |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4162282A (en) | 1976-04-22 | 1979-07-24 | Coulter Electronics, Inc. | Method for producing uniform particles |
| US4310505A (en) | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4533254A (en) | 1981-04-17 | 1985-08-06 | Biotechnology Development Corporation | Apparatus for forming emulsions |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4728575A (en) | 1984-04-27 | 1988-03-01 | Vestar, Inc. | Contrast agents for NMR imaging |
| US4921706A (en) | 1984-11-20 | 1990-05-01 | Massachusetts Institute Of Technology | Unilamellar lipid vesicles and method for their formation |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| IL79559A0 (en) | 1986-07-29 | 1986-10-31 | Univ Ramot | Contrast agents for nmr medical imaging |
| US4728578A (en) | 1986-08-13 | 1988-03-01 | The Lubrizol Corporation | Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5305757A (en) | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5228446A (en) | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US5639441A (en) | 1992-03-06 | 1997-06-17 | Board Of Regents Of University Of Colorado | Methods for fine particle formation |
| US5858399A (en) | 1992-04-09 | 1999-01-12 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| WO1993020802A1 (en) | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US5545396A (en) | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US6123919A (en) | 1994-04-08 | 2000-09-26 | The Trustees Of Princeton University | Magnetic resonance imaging using hyperpolarized noble gases |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| DE69617719D1 (de) | 1995-10-20 | 2002-01-17 | Air Liquide | Pharmazeutische zusammensetzung von stickstoffmonoxid |
| US6413544B1 (en) | 1996-08-19 | 2002-07-02 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US6548047B1 (en) * | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US6050444A (en) | 1998-07-22 | 2000-04-18 | Sugg; James Wesley | Consumable beverage dispenser with one-way valve |
| DE19910986C2 (de) | 1999-03-11 | 2001-06-07 | Aga Ab | Verwendung von Xenon bei der Behandlung von Neurointoxikationen |
| GB9913677D0 (en) | 1999-06-11 | 1999-08-11 | Imperial College | Formulation |
| DE19933704A1 (de) | 1999-07-19 | 2001-01-25 | Michael Georgieff | Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration |
| GB9917822D0 (en) | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| DE10054563A1 (de) | 2000-11-03 | 2002-05-16 | Messer Griesheim Gmbh | Verfahren und Vorrichtung zur Betonherstellung |
| AU2002220881A1 (en) | 2000-12-04 | 2002-06-18 | Uws Ventures Limited | Noble gas complexes |
| DE60111917T2 (de) | 2001-01-31 | 2006-04-20 | Bracco International B.V. | Lyophilisierbares Kontrastmittel, gasgefüllte Mikrobläschen enthaltend |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| CA2456977C (en) | 2001-08-16 | 2011-06-07 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| US7202089B2 (en) * | 2001-09-14 | 2007-04-10 | Alan Kleinfeld | Early diagnosis of stroke |
| GB0209998D0 (en) | 2002-05-01 | 2002-06-12 | Protexeon Ltd | Use |
| JP2005533062A (ja) * | 2002-06-12 | 2005-11-04 | メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | キセノン含有ガスによる脳保護 |
| DE10328272A1 (de) | 2002-06-22 | 2004-01-15 | Messer Griesheim Gmbh | Medikament mit Xenon und NO |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| WO2004004782A1 (de) | 2002-07-05 | 2004-01-15 | Messer Griesheim Gmbh | Xenon enthaltendes adjuvans |
| GB0218153D0 (en) | 2002-08-05 | 2002-09-11 | Ic Innovations Ltd | An analgesic agent for newborn or retal subjects |
| DE10336768B4 (de) | 2002-08-10 | 2010-09-09 | Air Liquide Deutschland Gmbh | Medikament zur Verbesserung der Sauerstoffutilation |
| DE10336778B4 (de) | 2002-08-10 | 2010-09-16 | Air Liquide Deutschland Gmbh | Stabilisierung eines Patienten mit einem xenonhaltigen Gas |
| MXPA05003287A (es) | 2002-09-28 | 2005-07-05 | Massachusetts Inst Technology | Influenza terapeutica. |
| US7923032B2 (en) | 2002-11-26 | 2011-04-12 | Seacoast Neuroscience, Inc. | Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| FR2849779B1 (fr) | 2003-01-15 | 2006-07-14 | Air Liquide Sante Sa | Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques |
| US7198179B2 (en) | 2003-02-25 | 2007-04-03 | Therox, Inc. | System for storing and dispensing a gas-solubilized product |
| US20060019868A1 (en) | 2004-01-30 | 2006-01-26 | Pendharkar Sanyog M | Hemostatic compositions and devices |
| WO2005034966A1 (en) | 2003-10-10 | 2005-04-21 | Protexeon Limited | Use of xenon with hypothermia for treating neonatal asphyxia |
| EP1552840A1 (en) | 2004-01-07 | 2005-07-13 | Aga Ab | Use of a xenon/carbon monoxide mixture for the protection of cells |
| GB0418540D0 (en) | 2004-08-19 | 2004-09-22 | Protexeon Ltd | Use |
| EP1714642A1 (en) * | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
| AU2005332157A1 (en) | 2005-05-23 | 2006-11-30 | Mebiopharm Co., Ltd., | Method of producing liposomes containing gas enclosed therein |
| MX2008013618A (es) | 2006-05-09 | 2008-10-30 | Colgate Palmolive Co | Regimen para el cuidado oral. |
| US7976743B2 (en) * | 2006-10-16 | 2011-07-12 | Northwestern University | Gas-containing liposomes |
| US20080187605A1 (en) | 2007-02-02 | 2008-08-07 | Olney John W | Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems |
| US9814672B2 (en) | 2007-03-09 | 2017-11-14 | Susan T. Laing | Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi |
| EP1980260A1 (en) | 2007-04-10 | 2008-10-15 | Nicholas Peter Franks | Use of hyperbaric conditions to provide neuroprotection |
| US8435569B2 (en) | 2007-04-30 | 2013-05-07 | Nnoxe Pharmaceutiques Inc. | Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon |
| ITMI20071031A1 (it) | 2007-05-22 | 2008-11-23 | Acetilene & Deriv Ati Siad Spa | Uso di xenon per la protezione di organi da danno ischemico |
| EP2229147A2 (en) | 2007-12-03 | 2010-09-22 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| JP2011506432A (ja) * | 2007-12-10 | 2011-03-03 | エピターゲット・アーエス | 非ラメラ形成脂質を含む音響感受性薬物送達粒子 |
| CL2007003772A1 (es) | 2007-12-21 | 2008-04-25 | Vulco Sa | Procedimiento para la fabricacion de un mandril flexible de poliuretano, que contiene un alma metalica que comprende recubrir con goma un alma metalica, aplicar desmoldante, precalentar el conjunto, curar el poliuretano y enfriar el codo. |
| US8618056B2 (en) * | 2007-12-22 | 2013-12-31 | Cuthbert O. Simpkins | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| EP3597201A3 (en) | 2008-11-10 | 2020-03-04 | Moleac Pte Ltd. | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
| CN102300555B (zh) | 2009-01-30 | 2015-06-17 | 卡斯伯特·O·辛普金斯 | 复苏液 |
| FR2944969B1 (fr) | 2009-04-29 | 2011-08-26 | Air Liquide | Utilisation de n2o gazeux dans le traitement des douleurs chroniques |
| WO2010132711A1 (en) | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| KR101875843B1 (ko) * | 2009-06-22 | 2018-07-06 | 디퓨젼 파마슈티컬즈 엘엘씨 | 확산 촉진 화합물 및 그 화합물 단독 또는 혈전 용해제와 합쳐진 화합물의 용도 |
| US8974818B2 (en) | 2010-01-20 | 2015-03-10 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
| FR2956323B1 (fr) | 2010-02-15 | 2013-12-20 | Air Liquide | Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques |
| CA2806639C (en) | 2010-08-09 | 2020-10-20 | Bracco Suisse Sa | Targeted gas-filled microvesicles |
| CN103491976B (zh) * | 2011-01-14 | 2015-04-01 | 卡思伯特·O·辛普金斯 | 用于处理与缺乏血液供给、休克和神经损伤相关的疾病的方法和组合物 |
| US20130247924A1 (en) | 2012-03-23 | 2013-09-26 | Mark Scatterday | Electronic cigarette having a flexible and soft configuration |
| CN103565745A (zh) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
-
2012
- 2012-09-21 CN CN201210356929.9A patent/CN103565745A/zh active Pending
- 2012-09-21 CN CN201910643063.1A patent/CN110464709A/zh active Pending
-
2013
- 2013-08-09 EP EP13828100.1A patent/EP2882422B1/en active Active
- 2013-08-09 AU AU2013299453A patent/AU2013299453B2/en active Active
- 2013-08-09 EP EP21170435.8A patent/EP3932394B1/en active Active
- 2013-08-09 CA CA3132444A patent/CA3132444C/en active Active
- 2013-08-09 CA CA2881096A patent/CA2881096C/en active Active
- 2013-08-09 WO PCT/US2013/054349 patent/WO2014026117A2/en not_active Ceased
- 2013-08-09 US US14/420,429 patent/US10369103B2/en active Active
- 2013-08-09 JP JP2015526733A patent/JP6297040B2/ja active Active
-
2019
- 2019-06-26 US US16/453,252 patent/US10973764B2/en active Active
-
2021
- 2021-04-13 US US17/229,627 patent/US11872312B2/en active Active
-
2023
- 2023-12-14 US US18/540,656 patent/US20240398708A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015528441A5 (https=) | ||
| JP6433079B2 (ja) | 線維化抑制のための薬物担体および薬物担体キット | |
| Szebeni et al. | Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome | |
| JP5873858B2 (ja) | 膜貫通薬物送達システムに適用するためのプロサポシン由来の融合タンパク質又はポリペプチドを含む組成物 | |
| JP5587762B2 (ja) | 膣内送達により子宮頸部異形成を治療するための二相性脂質小胞組成物および方法 | |
| JP6297040B2 (ja) | 脳卒中の治療のための神経保護リポソーム組成物および方法 | |
| US20250195621A1 (en) | Synthetic platelets | |
| CN104884065A (zh) | 治疗癌症的方法 | |
| JP2015515992A5 (https=) | ||
| EP2148662A1 (en) | Ultrasound imaging with targeted microbubbles | |
| CN117120028A (zh) | 使用载剂靶向递送治疗剂的组合物和方法 | |
| JP2009532371A5 (https=) | ||
| AU2021256086A1 (en) | Methods for treating acute conditions using lipid binding protein- based complexes | |
| WO2018071837A1 (en) | Radiofrequency field hyperthermia and solid tumor immunomodulation | |
| TW202010536A (zh) | 誘發免疫反應之原位方法 | |
| JP2008050375A (ja) | 線維化抑制のための薬物担体および薬物担体キット | |
| US20230181759A1 (en) | Compositions for treatment of viral respiratory infections and methods of use thereof | |
| US20170050945A1 (en) | Compositions and methods for the treatment of sarcoidosis | |
| WO2005004914A1 (ja) | NF-κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法 | |
| IL322074A (en) | Treatment using a lipid-binding protein molecule | |
| CN116115770A (zh) | 一种微环境重塑中药纳米气弹及其制备方法和应用 | |
| JP2024528010A (ja) | 気管支肺異形成症（ｂｐｄ）及びｂｐｄ関連肺高血圧症の治療のための組成物及び方法 | |
| Shah et al. | Surface-active drug loaded lipopolymeric nanohybrid aerosol therapy: potential non-invasive way to mitigate lipopolysaccharide mediated inflammation in murine lungs | |
| CA3182210A1 (en) | Methods and compositions for treating coronavirus infectious disease | |
| JP2025512987A (ja) | 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 |